

Synthesis and Evaluation as Antitubercular Agents of 5-Arylethenyl and 5-(Hetero)aryl-3-Isoxazolecarboxylate

Claudia Vergelli,¹ Agostino Cilibrizzi,¹ Letizia Crocetti,¹ Alessia Graziano,¹ Vittorio Dal Piaz,¹ Baojie Wan,² Yuehong Wang,² Scott Franzblau,² and Maria Paola Giovannoni^{1*}

¹Dipartimento di Scienze Farmaceutiche, University of Florence, via Ugo Schiff 6, 50019 Sesto Fiorentino, Florence, Italy

²Institute for Tuberculosis Research, University of Illinois at Chicago, Chicago, IL 60612, USA

Strategy, Management and Health Policy				
Enabling Technology, Genomics, Proteomics	Preclinical Research	Preclinical Development Toxicology, Formulation Drug Delivery, Pharmacokinetics	Clinical Development Phases I-III Regulatory, Quality, Manufacturing	Postmarketing Phase IV

ABSTRACT A new series of 5-aryl and 5-arylethenylisoxazole carboxylate derivatives was synthesized and evaluated for in vitro activity against *Mycobacterium tuberculosis* H₃₇R_v. Several compounds exhibited minimum inhibitory concentrations in the low micromolar range (2.3–11.4 μM). A variety of substituents introduced around the isoxazole ring allowed the delineation of preliminary SARs for this new series of compounds. Drug Dev Res 74 : 162–172, 2013. © 2012 Wiley Periodicals, Inc.

Key words: *Mycobacterium tuberculosis*; antituberculosis agents; 3-isoxazolecarboxylic acid alkyl esters

INTRODUCTION

Tuberculosis (TB) is a chronic and often deadly infectious disease caused by various species of *Mycobacterium*, mainly *Mycobacterium tuberculosis* (*Mtb*) [Russell et al., 2010]. The World Health Organization (WHO) has estimated that one-third of the world's population is infected with *Mtb*, resulting in 9.4 million new TB cases and 1.7 million deaths from TB in 2009, for the most part in developing countries [World Health Organization, 2010; World Health Organization, 2010/2011].

Despite the severe worldwide impact of TB, it remains a neglected disease as demonstrated by the evidence that no new anti-TB drugs have been introduced in therapy over the past 40 years [Janin, 2007; Spigelman, 2007] with rifampin (RMP), discovered in 1966, the most recent drug in this field [Maggi et al., 1966]. At present, only a few drug candidates are in Phase II clinical trials, e.g., PA-824 [Stover et al., 2000] and TMC-207 [Andries et al., 2005] (Fig. 1).

For many years, TB was considered a poverty-related disease, but it now occurs in the developed world. This is due to several reasons, the most important being the development of new virulent strains, resistant to antitubercular drugs, as well as the stream of immigrants from countries where TB is endemic. In addition, the recurrence of TB is directly connected to the explosive spread of HIV as the number of HIV-positive patients coinfecting with *Mtb* is constantly rising [Brooks et al., 2009]. WHO reports that one third of HIV-infected people are coinfecting with TB [World

The authors declare no conflicts of interest.

*Correspondence to: Maria Paola Giovannoni, Dipartimento di Scienze Farmaceutiche, University of Florence, Via Ugo Schiff 6, Sesto Fiorentino 50019, Florence, Italy. E-mail: mariapaola.giovannoni@unifi.it

Received 24 October 2012; Accepted 1 December 2012

Published online in Wiley Online Library (wileyonlinelibrary.com). DOI: 10.1002/ddr.21057




Fig. 1. Examples of anti-TB agents.

Health Organization, 2002], and 90% of these die within a few months of the appearance of clinical symptoms. This situation has prompted the WHO to declare TB as a global emergency [Janin, 2007].

The current standard therapy, Directly Observed Therapy Short-course [World Health Organization, 2009] is based on a combination of isoniazide (INH), Rifampin (RMP), pyrazinamide, and ethambutol (or streptomycin) for 2 months followed by further treatment with INH and RMP for an additional 4–7 months. This long treatment regimen is necessary

because of the presence of a nonreplicating persistent *Mtb* phenotype (NRP-TB) [Wayne and Sohaskey, 2001] is often associated with poor patient compliances that contribute to the development of multidrug resistance. There are two types of drug resistance: multidrug resistant TB (MDR-TB) and extensively drug resistant TB (XDR-TB) [Johnson et al., 2006; Dorman and Chaisson, 2007]; the former defined as resistance to at least INI and RMP (MDR-TB) and the latter including concomitant resistance to any fluoroquinolone and at least one second-line drug, e.g.




Fig. 2. Reagent and conditions: (A) ArCHO, EtONa, EtOH, 0°C, 2–20 h; (B) NaOH, EtOH, r.t., 1 h; (C) ROH, H₂SO₄, 80°C, 30–90 min.

kanamycin, amikacin, or capreomycin (XDR-TB). These data highlight the need for new, safer, and more potent anti-TB agents with novel mechanisms of action.

Many classes of organic compounds have been synthesized and tested as anti-TB agents, and in particular nitrogen heterocycles derivatives such as isoxazolines or isoxazoles have been described as good in vitro antitubercular agents [Johar et al., 2005; Janin, 2007; Eswarana et al., 2010]. Some representative compounds with this scaffold are shown in Figure 1. The isoxazolines **A** and **B** [Tangalappally et al., 2007] and the isoxazole derivatives **C** [Pieroni et al., 2009] and **D** [Lilienkamp et al., 2010] had interesting levels of activity against *Mtb* with minimum inhibitory concentration (MIC) values in the low or submicromolar range.

In this article, we describe the synthesis and the biological activity of a new series of anti-TB compounds with an isoxazole scaffold (Fig. 1, structure **E**), structurally related to compounds **C** and **D**. Various substituents were introduced around the isoxazole core in order to find the best substitution pattern and to define the importance of different substituents.

MATERIALS AND METHODS

Chemistry

All the final compounds were synthesized as reported in Figures 2 and 3. Figure 2 shows the synthetic procedure leading to the 4-benzoyl-5-styrylisoxazoles **2a–f** and **4a–c**. The precursors were represented by previously described isoxazoles **1a,b** [Renzi et al., 1968; Dal Piaz et al., 1991], which were condensed with the appropriate arylaldehydes to give the corresponding vinyl derivatives **2a–f**. Hydrolysis of **2a** and **2f** gives intermediate carboxylic acids **3a,b** which, in turn, were transformed into the ester derivatives **4a–c** using the appropriate alcohol and conc. H₂SO₄ at 80°C. Figure 2 shows the synthesis of the 4-unsubstituted derivatives **8a–g** and **10 a–e**. The key intermediates **7a–g** (**7a** [Fatutta and Balestra, 1958]; **7b** [Thormann et al., 2008]; **7c** [Deavegowda et al., 2010]; **7f** [Janculev and Podolesov, 1961]; **7g** [Patil et al., 2007] were obtained by condensation of commercially available **5a–g** and diethyl oxalate **6** [Fatutta and Balestra, 1958] and transformed into the final isoxazoles **8a–g** by treatment with hydroxylamine hydrochloride in ethanol and H₂SO₄. Finally, for compounds **8a–e**, a




Fig. 3. Reagent and conditions: (A) Na, Et₂O, r.t-40°C; (B) NH₂OH.HCl, H₂SO₄, EtOH, reflux; (C) 1 N NaOH, EtOH, rt-60°C; (D) iC₃H₇OH, H₂SO₄, reflux.

further transformation in the corresponding isopropyl esters (**10a-e**) was performed following the same procedure described for compounds **4a-c**.

Experimental

All melting points were determined on a Büchi apparatus and are uncorrected. ¹H-NMR spectra were recorded with an Avance 400 instrument (Bruker Biospin Version 002 with SGU, Bruker AXS Inc., Madison, WI USA). Chemical shifts are reported in ppm, using the solvent as internal standard. Extracts were dried over Na₂SO₄, and the solvents were removed under reduced pressure. Merck F-254 commercial plates (Merck-Gruppe, Darmstadt, Germany) were used for analytical thin layer chromatography (TLC) to follow the reaction course. Silica gel 60 (Merck 70–230 mesh) was used for column chromatography. Microanalyses were performed with a Perkin-Elmer 260 elemental analyzer (Perkin-Elmer, Waltham, MA USA) for C, H, and N. Results were within ±0.4% of the theoretical values unless otherwise stated. Reagents and starting materials were commercially available.

General Procedures for 2a-f

To a cooled (0°C) and stirred mixture of **1a,b** [Renzi et al., 1968; Dal Piaz et al., 1991] (3.86 mmol) and the appropriate arylaldehyde (3.86 mmol) in 4–6 ml of anhydrous EtOH, a solution of sodium ethoxide, obtained from sodium (7.72 mmol) and anhydrous EtOH (5 ml), was slowly added. The mixture was stirred at 0°C for 2–20 h, then it was acidified with 6 N HCl and diluted with 30 ml of cold water. The final compounds were recovered by suction and purified by crystallization.

4-Benzoyl-5-Styryl-Isoxazole-3-Carboxylic Acid Ethyl Ester, 2a

Yield = 67%; mp = 56°C (EtOH); ¹H-NMR (DMSO-d₆) δ 0.97 (t, 3H, CH₃CH₂, J = 7.2 Hz), 4.07 (q, 2H, CH₃CH₂, J = 7.2 Hz), 7.13 (d, 1H, CH = CH, J = 16.8 Hz), 7.45–7.49 (m, 3H, Ar), 7.58 (m, 2H, Ar), 7.62–7.78 (m, 4H: 3H, Ar; 1H, CH = CH), 7.82 (m, 2H, Ar). MS *m/z* 348 [M⁺]. Anal. Calcd for C₂₁H₁₇NO₄: C, 72.61; H, 4.93; N, 4.03. Found C, 7.40; H, 4.92; N, 4.04.

4-Benzoyl-5-[2-(4-Chlorophenyl)-Vinyl]-Isoxazole-3-Carboxylic Acid Ethyl Ester, 2b

Yield = 75%; mp = 75–77°C (Et₂O); ¹H-NMR (DMSO-d₆) δ 0.96 (t, 3H, CH₃CH₂, J = 7.2 Hz), 4.07 (q, 2H, CH₃CH₂, J = 7.2 Hz), 7.15 (d, 1H, CH = CH, J = 16.8 Hz), 7.48 (m, 2H, Ar), 7.58 (m, 2H, Ar), 7.70–7.78 (m, 4H: 3H, Ar; 1H, CH = CH), 7.82 (m, 2H, Ar). MS *m/z* 382 [M⁺]. Anal. Calcd for C₂₁H₁₆ClNO₄: C, 66.06; H, 4.22; N, 3.67. Found C, 66.22; H, 4.23; N, 3.68.

4-Benzoyl-5-[2-(3-Chlorophenyl)-Vinyl]-Isoxazole-3-Carboxylic Acid Ethyl Ester, 2c

Yield = 67%; mp = 68–70°C (Et₂O); ¹H-NMR (CDCl₃) δ 1.08 (t, 3H, CH₃CH₂, J = 7.2 Hz), 4.13 (q, 2H, CH₃CH₂, J = 7.2 Hz), 7.05 (d, 1H, CH = CH, J = 16.4 Hz), 7.30–7.40 (m, 3H, Ar), 7.50–7.60 (m, 4H: 3H, Ar; 1H, CH = CH), 7.65 (m, 1H, Ar), 7.82 (m, 2H, Ar). MS *m/z* 382 [M⁺]. Anal. Calcd for C₂₁H₁₆ClNO₄: C, 66.06; H, 4.22; N, 3.67. Found C, 66.20; H, 4.21; N, 3.67.

4-Benzoyl-5-(2-Naphthalen-1-yl-Vinyl)-Isoxazole-3-Carboxylic Acid Ethyl Ester, 2d

Yield = 48%; mp = 137–139°C (Et₂O); ¹H-NMR (DMSO-d₆) δ 1.00 (t, 3H, CH₃CH₂, J = 7.2 Hz), 4.10 (q, 2H, CH₃CH₂, J = 7.2 Hz), 7.24 (d, 1H, CH = CH, J = 16.4 Hz), 7.50–7.65 (m, 5H, Ar), 7.73 (m, 1H, Ar), 7.90 (m, 2H, Ar), 7.95 (m, 1H, Ar), 7.98–8.04 (m, 2H, Ar), 8.20 (m, 1H, Ar), 8.40 (d, 1H, CH = CH, J = 16.4 Hz). MS *m/z* 398 [M⁺]. Anal. Calcd for C₂₅H₁₉NO₄: C, 75.55; H, 4.82; N, 3.52. Found C, 75.31; H, 4.81; N, 3.51.

4-(4-Chlorobenzoyl)-5-(2-Naphthalen-1-yl-Vinyl)-Isoxazole-3-Carboxylic Acid Ethyl Ester, 2e

Yield = 28%; mp = 125–126°C (EtOH); ¹H-NMR (CDCl₃) δ 1.20 (t, 3H, CH₃CH₂, J = 7.2 Hz), 4.24 (q, 2H, CH₃CH₂, J = 7.2 Hz), 7.12 (d, 1H, CH = CH, J = 16.4 Hz), 7.50 (d, 2H, Ar, J = 8.4 Hz), 7.57–7.64 (m, 3H, Ar), 7.77 (m, 1H, Ar), 7.80–7.90 (m, 2H, Ar), 7.92 (d, 2H, Ar, J = 8.4 Hz), 8.17 (m, 1H, Ar), 8.48 (d, 1H, CH = CH, J = 16.4 Hz). MS *m/z* 432 [M⁺]. Anal. Calcd for C₂₅H₁₅ClNO₄: C, 69.53; H, 4.20; N, 3.24. Found C, 69.69; H, 4.21; N, 3.23.

4-Benzoyl-5-(2-Biphenyl-4-yl-Vinyl)-Isoxazole-3-Carboxylic Acid Ethyl Ester, 2f

Yield = 47%; mp = 128–129°C (EtOH); ¹H-NMR (CDCl₃) δ 1.10 (t, 3H, CH₃CH₂, J = 7.2 Hz), 4.15 (q, 2H, CH₃CH₂, J = 7.2 Hz), 7.10 (d, 1H, CH = CH, J = 16.4 Hz), 7.40 (m, 1H, Ar), 7.46–7.55 (m, 5H, Ar),

7.60–7.65 (m, 6H, Ar), 7.70 (d, 1H, CH = CH, J = 16.4 Hz), 7.85 (m, 2H, Ar). MS *m/z* 424 [M⁺]. Anal. Calcd for C₂₇H₂₁NO₄: C, 76.58; H, 5.00; N, 3.31. Found C, 76.77; H, 4.99; N, 3.32.

4-Benzoyl-5-(2-Biphenyl-4-yl-Vinyl)-Isoxazole-3-Carboxylic Acid, 3b

To a suspension of **2f** (0.28 mmol) in 2.5 ml of EtOH, 1 ml of 1N NaOH was added, and the mixture was stirred at room temperature for 1 h. After cooling, the mixture was acidified with 2N HCl and extracted with ethyl acetate (3 x 10 ml). Evaporation of the solvent under vacuum afforded the desired final compound. Yield = 73%; mp = 187–190°C (EtOH); ¹H-NMR (CDCl₃) δ 6.70 (d, 1H, CH = CH, J = 16.4 Hz), 7.36–7.68 (m, 11H: 10H, Ar; 1H, CH = CH), 7.70–7.87 (m, 3H, Ar), 8.05 (m, 2H, Ar). MS *m/z* 396 [M⁺]. Anal. Calcd for C₂₅H₁₇NO₄: C, 75.94; H, 4.33; N, 3.54. Found C, 75.73; H, 4.34; N, 3.54.

General Procedure for Compounds 4a–c

To a mixture of **3a** [Renzi et al., 1968] and **3b** (0.313 mmol) in 1.5–2 ml of the appropriate alcohol (methanol or isopropyl alcohol), 0.5 ml of conc. H₂SO₄ was added. The suspension was refluxed for 30–120 min, and after cooling, cold water was added, and the mixture was extracted with CH₂Cl₂ (3 x 15 ml). The solvent was evaporated in vacuum affording final compounds **4a** and **4b**. For compound **4c**, after dilution with water, the precipitate was recovered by suction and recrystallized with ethanol.

4-Benzoyl-5-Styryl-Isoxazole-3-Carboxylic Acid Methyl Ester, 4a

Yield = 94%; oil; ¹H-NMR (CDCl₃) δ 3.70 (s, 3H, CH₃), 7.03 (d, 1H, CH = CH, J = 16.4 Hz), 7.36–7.40 (m, 3H, Ar), 7.45–7.55 (m, 4H, Ar), 7.60–7.70 (m, 2H: 1H, Ar; 1H, CH = CH), 7.82 (d, 2H, Ar). MS *m/z* 334 [M⁺]. Anal. Calcd for C₂₀H₁₅NO₄: C, 72.06; H, 4.54; N, 4.20. Found C, 72.27; H, 4.55; N, 4.21.

4-Benzoyl-5-Styryl-Isoxazole-3-Carboxylic Acid Isopropyl Ester, 4b

Yield = 92%; oil; ¹H-NMR (CDCl₃) δ 1.06 (d, 6H, CH(CH₃)₂, J = 6.4 Hz), 5.03 (m, 1H, CH(CH₃)₂), 7.05 (d, 1H, CH = CH, J = 16.4 Hz), 7.35–7.40 (m, 3H, Ar), 7.42–7.55 (m, 4H, Ar), 7.60–7.70 (m, 2H: 1H, Ar; 1H, CH = CH), 7.85 (d, 2H, Ar). MS *m/z* 362 [M⁺]. Anal. Calcd for C₂₀H₁₅NO₄: C, 73.12; H, 5.30; N, 3.88. Found C, 72.91; H, 5.29; N, 3.89.

4-Benzoyl-5-(2-Biphenyl-4-yl-Vinyl)-Isoxazole-3-Carboxylic Acid Isopropyl Ester, 4c

Yield = 65%; mp = 123–125°C (EtOH); ¹H-NMR (CDCl₃) δ 1.07 (d, 6H, CH(CH₃)₂, J = 6.4 Hz), 5.03 (m, 1H, CH(CH₃)₂), 7.10 (d, 1H, CH = CH, J = 16.4 Hz), 7.35–7.56 (m, 6H, Ar), 7.60–7.77 (m, 6H: 5H, Ar, 1H, CH = CH), 7.82 (m, 1H, Ar), 7.85 (d, 2H, Ar). MS *m/z* 438 [M⁺]. Anal. Calcd for C₂₈H₂₃NO₄: C, 76.87; H, 5.30; N, 3.20. Found C, 76.85; H, 5.29; N, 3.21.

General Procedure for Compounds 7d and 7e

To a stirred mixture of the commercially available **5d** or **5e** (5.26 mmol) and diethyl oxalate (5–15 mmol) in anhydrous ether (50 ml), 5.25–7.40 mmol of Na was added in a dropwise manner. The suspension was stirred at room temperature for 4 h and then heated at 40°C for 4–7 h. After cooling, the precipitate was filtered off and washed with anhydrous ether. The solid was dissolved in water and acidified with 6N HCl to afford a crude precipitate that was collected by suction and purified by crystallization from ethanol.

4-Hydroxy-4-(7-Methoxybenzofuran-2-yl)-2-oxo-but-3-Enoic Acid Ethyl Ester, 7d

Yield = 85%; mp = 108–111°C (EtOH); ¹H-NMR (CDCl₃) δ 1.45 (t, 3H, CH₃CH₂, J = 7.2 Hz), 4.07 (s, 3H, OCH₃), 4.42 (q, 2H, CH₃CH₂, J = 7.2 Hz), 7.00 (m, 1H, Ar), 7.20 (s, 1H, Ar), 7.25–7.33 (m, 2H, Ar), 7.65 (s, 1H, Ar). MS *m/z* 291 [M⁺]. Anal. Calcd for C₁₅H₁₄O₆: C, 62.07; H, 4.86. Found C, 62.22; H, 4.85.

4-(2,6-Dimethoxypyridin-3-yl)-4-Hydroxy-2-oxo-but-3-Enoic Acid Ethyl Ester, 7e

Yield = 84%; mp = 86–89°C (EtOH); ¹H-NMR (CDCl₃) δ 1.43 (t, 3H, CH₃CH₂, J = 7.2 Hz), 4.03 (s, 3H, OCH₃), 4.12 (s, 3H, OCH₃), 4.40 (q, 2H, CH₃CH₂, J = 7.2 Hz), 6.45 (d, 1H, Ar, J = 8.8 Hz), 7.41 (s, 1H, Ar), 8.28 (d, 1H, Ar, J = 8.8 Hz). MS *m/z* 282 [M⁺]. Anal. Calcd for C₁₃H₁₅NO₆: C, 55.51; H, 5.38; N, 4.98. Found C, 55.68; H, 5.37; N, 4.99.

General Procedure for Compounds 8b, 8d-g

To a suspension of **7b** [Thormann et al., 2008] or **7d-g** [Janculev and Podolesov, 1961; Patil et al., 2007; Deavegowda et al., 2010] (0.51 mmol) and hydroxylamine hydrochloride (2.5–3.02 mmol, dissolved in 0.5 ml of water) in 2–6 ml of EtOH, 0.3–0.4 ml of conc. H₂SO₄ was added. The mixture was heated at 80°C for

15–45 min. After cooling, the solvent was evaporated under vacuum to afford a residue which, after treatment with cold water (15 ml), gave rise to a crude precipitate that was recovered by suction. The final compounds **8b**, **8e**, and **8g** were purified by crystallization, whereas compounds **8d** and **8f** were purified by column chromatography using toluene/ethyl acetate 9.5:0.5 as eluent.

5-Benzo[b]thiophen-2-yl-Isoxazole-3-Carboxylic Acid Ethyl Ester, 8b

Yield = 69%; mp = 130–131°C, dec. (EtOH); ¹H-NMR (CDCl₃) δ 1.47 (t, 3H, CH₃CH₂, J = 7.2 Hz), 4.51 (q, 2H, CH₃CH₂, J = 7.2 Hz), 6.92 (s, 1H, isoxazole), 7.45 (m, 2H, Ar), 7.85 (s, 1H, Ar), 7.90 (m, 2H, Ar). MS *m/z* 274 [M⁺]. Anal. Calcd for C₁₄H₁₁NO₃S: C, 61.52; H, 4.06; N, 5.12. Found C, 61.64; H, 4.07; N, 5.11.

5-(7-Methoxybenzofuran-2-yl)-Isoxazole-3-Carboxylic Acid Ethyl Ester, 8d

Yield = 40%; mp = 119–121°C; purified by column chromatography (toluene/ethyl acetate 9.5:0.5); ¹H-NMR (CDCl₃) δ 1.45 (t, 3H, CH₃CH₂, J = 7.2 Hz), 4.07 (s, 3H, OCH₃), 4.50 (q, 2H, CH₃CH₂, J = 7.2 Hz), 6.93 (m, 1H, Ar), 7.14 (s, 1H, isoxazole), 7.24–7.30 (m, 2H, Ar), 7.36 (s, 1H, Ar). MS *m/z* 288 [M⁺]. Anal. Calcd for C₁₅H₁₃NO₅: C, 62.72; H, 4.56; N, 4.88. Found C, 62.94; H, 4.57; N, 4.87.

5-(2,6-Dimethoxypyridin-3-yl)-Isoxazole-3-Carboxylic Acid Ethyl Ester, 8e

Yield = 82%; mp = 131–133°C, (Ether); ¹H-NMR (CDCl₃) δ 1.47 (t, 3H, CH₃CH₂, J = 7.2 Hz), 4.01 (s, 3H, OCH₃), 4.13 (s, 3H, OCH₃), 4.50 (q, 2H, CH₃CH₂, J = 7.2 Hz), 6.48 (d, 1H, Ar, J = 8.4 Hz), 7.05 (s, 1H, isoxazole), 8.19 (d, 1H, Ar, J = 8.4 Hz). MS *m/z* 279 [M⁺]. Anal. Calcd for C₁₃H₁₄N₂O₅: C, 56.11; H, 5.07; N, 10.07. Found C, 56.24; H, 5.06; N, 10.04.

5-(9H-Fluoren-2-yl)-Isoxazole-3-Carboxylic Acid Ethyl Ester, 8f

Yield = 68%; mp = 158–161°C, dec.; purified by column chromatography (toluene/ethyl acetate 9.5:0.5); ¹H-NMR (CDCl₃) δ 1.46 (t, 3H, CH₃CH₂, J = 7.2 Hz), 4.02 (s, 2H, PhCH₂Ph), 4.51 (q, 2H, CH₃CH₂, J = 7.2 Hz), 6.98 (s, 1H, isoxazole), 7.38–7.47 (m, 2H, Ar), 7.61 (m, 1H, Ar), 7.85–7.92 (m, 3H, Ar), 8.03 (s, 1H, Ar). MS *m/z* 306 [M⁺]. Anal. Calcd for C₁₉H₁₅NO₃: C, 74.74; H, 4.95; N, 4.59. Found C, 74.56; H, 4.96; N, 4.58.

5-Anthracen-9-yl-Isoxazole-3-Carboxylic Acid Ethyl Ester, **8g**

Yield = 74%; mp = 139–141°C, (EtOH); ¹H-NMR (CDCl₃) δ 1.53 (t, 3H, CH₃CH₂, J = 7.2 Hz), 4.60 (q, 2H, CH₃CH₂, J = 7.2 Hz), 7.09 (s, 1H, isoxazole), 7.51–7.57 (m, 4H, Ar), 7.80 (m, 2H, Ar), 8.10 (m, 2H, Ar), 8.67 (s, 1H, Ar). MS *m/z* 318 [M⁺]. Anal. Calcd for C₂₀H₁₅NO₃: C, 75.70; H, 4.76; N, 4.41. Found C, 75.88; H, 4.76; N, 4.42.

General Procedure for **9b** and **9d,e**

A mixture of **8b** or **8d,e** (0.91 mmol) and 1N NaOH (1–1.5 ml) in 3–4 ml of EtOH was stirred at room temperature for 20–30 min. For compound **9b**, the suspension was heated at 50°C for 30 min. After evaporation of the solvent under vacuum, water was added, and the suspension was acidified with 6N HCl (1–2 ml). The crude precipitate was recovered by suction (compounds **9b** and **9d**), whereas compound **9e** was extracted with ethyl acetate (3 × 20 ml).

5-Benzo[b]thiophen-2-yl-Isoxazole-3-Carboxylic Acid, **9b**

Yield = 47%; mp = 192–195°C, dec.; (EtOH); ¹H-NMR (DMSO-d₆) δ 7.41 (s, 1H, isoxazole), 7.49 (m, 2H, Ar), 7.99 (m, 1H, Ar), 8.10 (m, 1H, Ar), 8.18 (s, 1H, Ar). MS *m/z* 246 [M⁺]. Anal. Calcd for C₁₂H₇NO₃S: C, 58.77; H, 2.88; N, 5.71. Found C, 58.94; H, 2.87; N, 5.73.

5-(7-Methoxybenzofuran-2-yl)-Isoxazole-3-Carboxylic Acid, **9d**

Yield = 76%; mp = 179–182°C, dec.; (EtOH); ¹H-NMR (DMSO-d₆) δ 3.99 (s, 3H, OCH₃), 7.09 (m, 1H, Ar), 7.27–7.35 (m, 3H: 2H, Ar; 1H, isoxazole), 7.72 (s, 1H, Ar). MS *m/z* 260 [M⁺]. Anal. Calcd for C₁₃H₉NO₅: C, 60.24; H, 3.50; N, 5.40. Found C, 60.36; H, 3.51; N, 5.41.

5-(2,6-Dimethoxyppyridin-3-yl)-Isoxazole-3-Carboxylic Acid, **9e**

Yield = 56%; mp = 200–203°C, dec.; (EtOH); ¹H-NMR (DMSO-d₆) δ 3.96 (s, 3H, OCH₃), 4.08 (s, 3H, OCH₃), 6.59 (d, 2H, Ar, J = 8.4 Hz), 6.97 (s, 1H, isoxazole), 8.21 (d, 2H, Ar, J = 8.4 Hz). MS *m/z* 251 [M⁺]. Anal. Calcd for C₁₁H₁₀N₂O₅: C, 52.80; H, 4.03; N, 11.20. Found C, 52.94; H, 4.02; N, 11.17.

General Procedure for **10a–e**

Compounds **10a–e** were obtained starting from **9a–e** (compounds **9a** [Fatutta and Balestra, 1958] and

9c [Schneider et al., 2008]) following the general procedure described for compounds **4a–c**. For compounds **10b–d**, after dilution with cold water, the precipitate was recovered by suction and purified by crystallization, whereas compound **10e** was purified by column chromatography using cyclohexane/ethyl acetate 1/1 as eluent.

5-Biphenyl-4-yl-Isoxazole-3-Carboxylic Acid Isopropyl Ester, **10a**

Yield = 55%; mp = 101–103°C; (EtOH); ¹H-NMR (CDCl₃) δ 1.46 (d, 6H, CH(CH₃)₂, J = 6.4 Hz), 5.32–5.42 (m, 1H, CH(CH₃)₂), 6.97 (s, 1H, isoxazole), 7.43 (m, 1H, Ar), 7.50 (m, 2H, Ar), 7.67 (m, 2H, Ar), 7.75 (d, 2H, Ar, J = 8.4 Hz), 7.92 (d, 2H, Ar, J = 8.4 Hz). MS *m/z* 308 [M⁺]. Anal. Calcd for C₁₉H₁₇NO₃: C, 74.25; H, 5.58; N, 4.56. Found C, 74.50; H, 5.56; N, 4.57.

5-Benzo[b]thiophen-2-yl-Isoxazole-3-Carboxylic Acid Isopropyl Ester, **10b**

Yield = 85%; mp = 101–103°C, (cicloexane); ¹H-NMR (CDCl₃) δ 1.46 (d, 6H, CH(CH₃)₂, J = 6.4 Hz), 5.32–5.41 (m, 1H, CH(CH₃)₂), 6.91 (s, 1H, isoxazole), 7.45 (m, 2H, Ar), 7.85 (s, 1H, Ar), 7.89 (m, 2H, Ar). MS *m/z* 288 [M⁺]. Anal. Calcd for C₁₅H₁₃NO₃S: C, 62.70; H, 4.56; N, 4.87. Found C, 62.87; H, 4.57; N, 4.86.

5-Thiophen-2-yl-Isoxazole-3-Carboxylic Acid Isopropyl Ester, **10c**

Yield = 59%; mp = 53–56°C, (EtOH); ¹H-NMR (CDCl₃) δ 1.44 (d, 6H, CH(CH₃)₂, J = 6.4 Hz), 5.35 (m, 1H, CH(CH₃)₂), 6.79 (s, 1H, isoxazole), 7.17 (m, 1H, Ar), 7.52 (m, 1H, Ar), 7.59 (m, 1H, Ar). MS *m/z* 238 [M⁺]. Anal. Calcd for C₁₁H₁₁NO₃S: C, 55.68; H, 4.67; N, 5.90. Found C, 55.89; H, 4.67; N, 5.88.

5-(7-Methoxybenzofuran-2-yl)-Isoxazole-3-Carboxylic Acid Isopropyl Ester, **10d**

Yield = 82%; mp = 96–100°C; purified by column chromatography (cicloexane/ethyl acetate 1:1); ¹H-NMR (CDCl₃) δ 1.45 (d, 6H, CH(CH₃)₂, J = 6.4 Hz), 4.07 (s, 3H, OCH₃), 5.35 (m, 1H, CH(CH₃)₂), 6.93 (m, 1H, Ar), 7.13 (s, 1H, isoxazole), 7.26 (m, 2H, Ar), 7.36 (s, 1H, Ar). MS *m/z* 302 [M⁺]. Anal. Calcd for C₁₆H₁₅NO₅: C, 63.78; H, 5.02; N, 4.65. Found C, 63.59; H, 5.04; N, 4.66.

5-(2,6-Dimethoxyppyridin-3-yl)-Isoxazole-3-Carboxylic Acid Isopropyl Ester, **10e**

Yield = 86%; mp = 119–121°C, (EtOH); ¹H-NMR (CDCl₃) δ 1.45 (d, 6H, CH(CH₃)₂, J = 6.4 Hz), 4.00

(s, 3H, OCH₃), 4.13 (s, 3H, OCH₃), 5.35 (m, 1H, CH(CH₃)₂), 6.48 (d, 1H, Ar, J = 8.4 Hz), 7.04 (s, 1H, isoxazole), 8.19 (d, 1H, Ar, J = 8.4 Hz). MS *m/z* 293 [M⁺]. Anal. Calcd for C₁₄H₁₆N₂O₅: C, 57.53; H, 5.52; N, 9.58. Found C, 57.82; H, 5.53; N, 9.61.











Biological Assays

Microplate Almar blue assay (MABA) [Franzblau et al., 1998]

Test compound MICs against *Mtb* H₃₇RV (ATCC27294) were assessed by the MABA using RMP

and INH as positive controls. Compound stock solutions were prepared in DMSO at concentration of 12.8 mM, and the final test concentrations ranged from 128 μM to 0.5 μM. Twofold dilutions of compounds were prepared in Middlebrook 7H12 medium (7H9 broth containing 0.1% w/v casitone, 5.6 μg/ml palmitic acid, 5 mg/ml bovine serum albumin, 4 mg/ml catalase, filter-sterilizes) in a volume of 100 μl in 96-well microplates (BD Optilux™, 96-well Microplates, black/clear flat bottom; Becton, -Dickenson, Franklin Lakes, NJ USA). *Mtb* cultures (100 μl inoculum of 2 × 10⁵ cfu/ml) were added, yielding a final test volume of 200 μl. The

TABLE 1. Anti-TB Activity of Compounds 2a-f and 4a-c

Compound	R	Ar	X	MABA ^a MIC (μM)	LORA ^a MIC (μM)	Vero cell IC ₅₀ (μM)
 2a-f, 4a-c						
2a	C ₂ H ₅		H	58.2	96.6	95.17
2b	C ₂ H ₅		H	35.5	109.1	>128
2c	C ₂ H ₅		H	81.6	62.3	108.4
2d	C ₂ H ₅		H	26.9	54.7	>128
2e	C ₂ H ₅		Cl	>128	>128	ND ^b
2f	C ₂ H ₅		H	114.6	101.3	111.5
4a	CH ₃		H	26.8	54.1	88.07
4b	iC ₃ H ₇		H	61.2	>128	100.6
4c	iC ₃ H ₇		H	64.0	82.3	56.74
INH				0.4	>128	>128
RMP				0.1	1.9	110
PA-824				0.4	3.0	>128

^a*Mtb* strain H₃₇RV.

^bNot determined.

INH, isoniazide; LORA, low oxygen recovery assay; MABA, microplate Almar blue assay; MIC, minimum inhibitory concentration; RMP, rifampin.














plates were incubated at 37°C. On the seventh day of incubation, 12.5 µl of 20% Tween 80 and 20 µl of Alamar Blue (Invitrogen BioSource™; Life Technologies, Grand Island, NY USA) were added to the wells. After incubation at 37°C for 16–24 h, well fluorescence was measured (ex 530, em 590 nm). MICs were defined as the lowest concentration effecting a reduction in

fluorescence of ≥ 90% relative to the mean of replicate bacteria-only controls.

Low-Oxygen-Recovery Assay (LORA) [Cho et al., 2007]

A low-oxygen adapted culture of recombinant H₃₇Rv (pFCA-luxAB), expressing a *Vibrio harveyi*

TABLE 2. Anti-TB Activity of Compounds 8a–g and 10a–e

 8a-g, 10a-e					
Compound	R	Ar	MABA ^a MIC (µM)	LORA ^a MIC (µM)	Vero cell IC ₅₀ (µM)
8a	C ₂ H ₅		3.3	30.1	102
8b	C ₂ H ₅		2.7	25.3	>128
8c	C ₂ H ₅		3.5	58.9	>128
8d	C ₂ H ₅		2.2	13.1	>128
8e	C ₂ H ₅		>128	>128	ND ^b
8f	C ₂ H ₅		>128	>128	ND ^b
8g	C ₂ H ₅		>128	>128	ND ^b
10a	iC ₃ H ₇		2.3	63.5	>128
10b	iC ₃ H ₇		11.4	26.6	>128
10c	iC ₃ H ₇		2.4	14.0	>128
10d	iC ₃ H ₇		5.6	7.3	>128
10e	iC ₃ H ₇		>128	>128	ND ^b
INH			0.4	>128	>128
RMP			0.1	1.9	>128
PA-824			0.4	3.0	>128

^aMtb strain H₃₇Rv.

^bNot determined.

INH, isoniazide; LORA, low oxygen recovery assay; MABA, microplate Alamar blue assay; MIC, minimum inhibitory concentration; RMP, rifampin.

luciferase gene with an acetamidase promoter, was grown in a BiostatQ fermentor (Sartorius Group, Gottingen, Germany). Cells were collected on ice, washed in PBS, and stored at -80°C . Approximately 10^5 cfu/ml of thawed NRP cells were exposed to twofold serial dilutions of test compound in 7H9 broth in 96-well plates, incubated for 10 days anaerobically at 37°C . Luminescence readings were obtained following a 28-h recovery in an aerobic environment (5% CO_2). The data were analyzed graphically, and the lowest concentration of test compound preventing metabolic recovery (90% reduction relative to untreated cultures) was determined as described previously.

Cytotoxicity Assay [Falzari et al., 2005]

Cytotoxicity was determined by exposing different concentrations of samples to Vero cells. Briefly, samples were dissolved at 12.8 mM in DMSO. Six threefold dilutions were performed in growth medium MEM (Gibco, Grand Island, NY, USA), containing 10% fetal bovine serum (HyClone, Logan, UT, USA), 25 mM N-(2-hydroxyethyl)-piperazine-*N'*-2-ethanesulfonic acid (HEPES, Gibco), 0.2% NaHCO_3 (Gibco), and 2 mM glutamine (Irvine Scientific, Santa Ana, CA, USA). Final DMSO concentrations did not exceed 1% v/v. Compound dilutions were assayed in duplicate in 96-well tissue culture plates (Becton Dickinson Labware, Lincoln Park, NJ, USA) in a volume of 50 μl per well. An equal volume containing 5×10^5 log phase Vero cells (CCL-81; ATTC, Rockville, MD, USA) was added to each well, and cultures were incubated at 37°C in 5% CO_2 atmosphere. After 72 h, cell viability was measured using the CellTiter 96 aqueous nonradioactive cell proliferation assay (Promega Corp. Madison, WI, USA) according to the manufacturer's instructions. Absorbance at 490 nm was read in a Victor² multilabel reader (Perkin Elmer). The IC_{50} values were determined using a curve-fitting program.

RESULTS AND DISCUSSION

The activity of compounds **2a–f**, **4a–c**, **8a–g**, and **10a–e** was evaluated against *Mtb* TB strain H₃₇Rv in a MABA [Franzblau et al., 1998] and against NRP-TB in a LORA [Cho et al., 2007] with the activity expressed as MIC values (minimum inhibitory concentrations). Furthermore, toxicity to *Mtb* in an in vitro cytotoxicity test was assessed using Vero cells. (Tables 1 and 2). INH, RMP, and PA-824 were used as reference compounds.

Starting from 5-vinylisoxazoles **2a–f** and **4a–c** (Table 1), compounds show a low activity against *Mtb* with the only noteworthy observation being the difference of activity between compounds **2d** and **2e**, which

differ only by a chlorine in the para-position of benzoyl fragment. Compound **2d** was one of the more active in this series (MIC = 26.9 μM) with **2e** being inactive (MIC > 128 μM), suggesting that the chlorine is detrimental to activity. For most compounds, there is a correspondence between MABA and LORA values and with the exception of compounds **2b** and **2d** (Vero cell IC_{50} > 128 μM), they also showed little in vitro cytotoxicity (Vero cell $56.74 < \text{IC}_{50} < 128 \mu\text{M}$)

Data on the series of 5-(hetero)aryl-4-unsubstituted isoxazoles **8a–g** and **10a–e** are shown in Table 2. With the exception of compounds **8e**, **8f**, **8g**, and **10e** improved activity was observed as compared with the previous compounds. The residue *R* of the ester function can be changed as the 3-ethyl and the 3-isopropyl ester derivatives show comparable activity. However, there is a crucial role for the substituent at position 5. Compounds with a diphenyl, thiophene, benzothiophene, or a methoxybenzofurane had MIC values in the low micromolar range (MIC = 2.2–5.6 μM), whereas the introduction of aromatic portions endowed with major bulk (fluorene and anthracene nucleus) resulted to inactive compounds (**8f** and **8g**, MIC > 128 μM). The same inactivity was observed for the two 5-(2,6-dimethoxypyridine) derivatives, **8e** and **10e**, that contain a strongly basic nitrogen. An analogous activity trend occurred in the LORA, whereas MIC values were approximately an order of magnitude higher than in MABA. Moreover, with the exception of **8a**, all active compounds had no toxicity in Vero cell with IC_{50} values > 128 μM . These initial results suggest that position 4 of the isoxazole ring must be unsubstituted and the ethylenic spacer must be deleted from position 5 and the aromatic portion, with an appropriate steric hindrance directly linked to C-5 isoxazole. Further studies are in progress to better define the requirements in the isoxazole scaffold to improve anti-tubercular activity.

REFERENCES

- Andries K, Verhasselt P, Guillemont J, Gohlman HW, Neefs JM, Winkler H, Van Gestel J, Timmermann P, Zhu M, Lee E, et al. 2005. A diarylquinoline drug active and the ATP synthase of *Mycobacterium tuberculosis*. *Science* 307:223–227.
- Brooks JT, Kaplan JE, Holmes KK, Benson C, Pau A, Masur H. 2009. HIV-associated opportunistic infections, going, going, but not gone: the continued need for prevention and treatment guidelines. *Clin Infect Dis* 48:609–611.
- Cho SH, Warit S, Wan B, Hwang CH, Pauli GF, Franzblau SG. 2007. Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating *Mycobacterium tuberculosis*. *Antimicrob Agents Chemother* 51:1380–1385.
- Dal Piaz V, Ciciani G, Giovannoni MP. 1991. New 6-ciano-3-phenyl-1,2,3,4-tetrahydro-1,2-diazepin-5-ones: synthesis and in vitro anti-tumor activity evaluation. *Il Farmaco* 46:435–447.

- Deavegowda VN, Jung H, Han KC, Yang EG, Choo H, Pae AN, Nam G, Chai K. 2010. Novel 6-N-arylcarboxamidopyrazolo [4,3-d]pyrimidin-7-one derivatives as potential anti-cancer agents. *Bioorg Med Chem Lett* 20:1630–1633.
- Dorman SE, Chaisson RE. 2007. From magic bullets back to the magic mountain: the rise of extensively drug-resistant tuberculosis. *Nat Med* 3:295–298.
- Eswarana S, Adhikarib AV, Palc NK, Chowdhury IH. 2010. Design and synthesis of some new quinoline-3-carbohydrazone derivatives as potential antimycobacterial agents. *Bioorg Med Chem Lett* 20:1040–1044.
- Falzari K, Zhu Z, Pan D, Liu H, Hongmanee P, Franzblau SG. 2005. In vitro and in vivo activities of macrolide derivatives against *Mycobacterium tuberculosis*. *Antimicrob Agents Chemother* 49:1447–1454.
- Fatutta S, Balestra M. 1958. Ethyl p-phenylbenzoylpyruvate and its cyclization products. *Gazz Chim Ital* 88:899–909.
- Franzblau SG, Witzig RS, McLaughlin JC, Torres P, Madico G, Hernandez A, Degnan MT, Cook MB, Quenzer VK, Ferguson RM, et al. 1998. Rapid, low-technology MIC determination with clinical *Mycobacterium tuberculosis* isolates by using the microplate Alamar Blue assay. *J Clin Microbiol* 36:362–366.
- Janculev J, Podolsov B. 1961. Oxidative degradation of ethylaroyl pyruvates with lead tetraacetate. *Croat. Chem. Acta* 1:59–64.
- Janin YL. 2007. Antituberculosis drugs: ten years of research. *Bioorg Med Chem* 15:2479–2513.
- Johar M, Manning T, Kunimoto DY, Kumar R. 2005. Synthesis and in vitro anti-mycobacterial activity of 5-substituted pyrimidine nucleosides. *Bioorg Med Chem* 13:6663–6671.
- Johnson R, Streicher EM, Louw GE, Warren RM, Van Helden PD, Victor TD. 2006. Drug resistance *Mycobacterium tuberculosis*. *Curr Issues Mol Biol* 8:97–112.
- Lilienkampf A, Pieroni M, Wan B, Wang Y, Franzblau SG, Kozokowski AP. 2010. Rational design of 5-phenyl-3-isoxazolecarboxylic acid ethyl esters as growth inhibitors of *Mycobacterium tuberculosis*. A potent and selective series for further drug development. *J Med Chem* 53:678–688.
- Maggi N, Pasqualucci CR, Ballotta R, Sensi P. 1966. Rifampicin, a new orally active rifamycin. *Farmaco Sci* 21:68–75.
- Patil S, Kamath S, Sanchez T, Neamati N, Schinazi RF, Buolamvini JK. 2007. Synthesis and biological evaluation of novel 5(H)-phenanthridin-6-ones, 5(H)-phenanthridin-6-ones diketo acid analogs as new HIV-1 integrase inhibitors. *Bioorg Med Chem Lett* 15:1212–1228.
- Pieroni M, Lilienkampf A, Wan B, Wang Y, Franzblau SG, Kozikowski AP. 2009. Synthesis, biological evaluation and structure-activity relationship for 5-[(E)-2-arylethenyl]-3-isoxazolecarboxylic acid alkyl ester derivatives as valuable antitubercular chemotypes. *J Med Chem* 52:6287–6296.
- Renzi G, Dal Piaz V, Musante C. 1968. Condensation of chlorinated hydroxamic acid with β -oxobenzoyl compounds. *Gazz Chim Ital* 98:656–666.
- Russell DG, Barry CE, Flynn JL. 2010. Tuberculosis: what we don't know can, and does, hurt us. *Science* 328:852–856.
- Spigelman MK. 2007. New tuberculosis therapeutics: a growing pipeline. *J Infect Dis* 196:S28–S34.
- Stover C, Warrener P, Vandevanter DR, Sherman DR, Arain TM, Langhorne MH, Anderson SW, Towell JA, Yuan Y, McMurray DN, et al. 2000. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. *Nature* 405:962–966.
- Tangalapally RP, Sun D, Rakesh P, Budha N, Lee RB, Lenaerts AJ, Meibohm B, Lee RE. 2007. Discovery of novel isoxazolines as anti-tuberculosis agents. *Bioorg Med Chem Lett* 17:6638–6642.
- Thormann M, Almstetter M, Tremml A, Heiser U, Buncholz M, Niestroj AJ. 2008. 3-Hydroxy-1,5-dihydropyrrol-2-one derivatives as inhibitors of glutamyl cyclase for the treatment of ulcer, cancer and other diseases. *PCT Int. Appl. WO* 2008055945.
- Wayne LG, Sohaskey CD. 2001. Nonreplicating persistence of *Mycobacterium tuberculosis*. *Annu Rev Microbiol* 55:139–163.
- World Health Organization. 2002. Strategic framework to decrease the burden of TB/HIV document WHO/CDS/TB2002, 296, WHO/HIV AIDS/2002, 2. Geneva, Switzerland: World Health Organization.
- World Health Organization. The Five Elements of DOTS. 2009. Geneva: World Health Organization. <http://www.who.int/tb/dots/whatisdots/en/index.html>.
- World Health Organization. 2010. Tuberculosis fact sheet No. 104.
- World Health Organization. 2010/2011. Tuberculosis, tuberculosis global facts.